Nightstar Appoints Strategic Biotechnology Executive Paula Cobb to its Board of Directors
13 September 2018 - 8:05PM
Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage
gene therapy company developing treatments for rare inherited
retinal diseases, today announced that the company has appointed
strategic biotechnology executive Paula Cobb to its board of
directors.
“We are very happy to welcome Paula to our board of directors
and working alongside the very strong team we have built at
Nightstar,” said David Fellows, chief executive officer of
Nightstar. “Paula brings strategic, worldwide commercialization
experience in rare diseases having led teams to three new drug
approvals and playing key roles on four product launches, which
will be invaluable as Nightstar evolves into a commercial-stage
company.”
Ms. Cobb currently serves as the executive vice president of
corporate development at Decibel Therapeutics, Inc. Prior to
joining Decibel, she served as senior vice president of the rare
disease group at Biogen, where she was responsible for the
company’s marketed hemophilia assets and Phase 3 programs in spinal
muscular atrophy and neuropathic pain. Prior to this role, she
managed the multiple sclerosis franchise, led new product
commercialization for early pipeline programs, served as chief of
staff to the CEO and held various operational management roles with
Biogen in Europe. Before Biogen, she worked for various consulting
groups in the Boston area. Ms. Cobb graduated cum laude from
Amherst College with a B.A. degree in political science and
English. She also received an MBA from Harvard University Graduate
School of Business Administration.
About Nightstar
Nightstar is a leading clinical-stage gene
therapy company focused on developing and commercializing novel
one-time treatments for patients suffering from rare inherited
retinal diseases that would otherwise progress to blindness.
Nightstar’s lead product candidate, NSR-REP1, is currently in Phase
3 development for the treatment of patients with choroideremia, a
rare, degenerative, genetic retinal disorder that has no treatments
currently available and affects approximately one in every 50,000
people. Positive results from a Phase 1/2 trials of NSR-REP1 were
published in The Lancet in 2014 and
in The New England Journal of
Medicine in 2016. Nightstar’s second product
candidate, NSR-RPGR, is currently being evaluated in a clinical
trial known as the XIRIUS trial for the treatment of patients with
X-linked retinitis pigmentosa, an inherited X-linked recessive
retinal disease that affects approximately one in every 40,000
people.
For more information about Nightstar or its clinical trials,
please visit www.nightstartx.com.
Cautionary Language Concerning Forward-Looking
Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. The words “believe,” “anticipate,” “could,” “intend,”
“estimate,” “will,” “would,” “may,” “should,” “project,” “target,”
“track,” “expect” or other similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. All
statements contained in this press release other than statements of
historical facts are forward-looking statements, including, without
limitation: our potential commercialization of our product
candidates, our planned and ongoing clinical trials for NSR-REP1
and NSR-RPGR, including our Phase 3 STAR trial in choroideremia and
Phase 1/2 XIRIUS trial in X-linked retinitis pigmentosa, the
prevalence of patient populations for our targeted indications, and
the utility of prior preclinical and clinical data in determining
future clinical results. These forward-looking statements are based
on management's current expectations of future events as of the
date of this release and are subject to a number of substantial
known and unknown risks, uncertainties and other factors that may
cause our actual results, levels of activity, performance or
achievements to be materially different from the information
expressed or implied by these forward-looking statements, including
those related to the timing and costs involved in commercializing
any product candidate that receives regulatory approval; the
initiation, timing and conduct of clinical trials; the availability
of data from clinical trials and expectations for regulatory
submissions and approvals; our scientific approach and general
development progress; the availability or commercial potential of
the our product candidates; the sufficiency of our cash resources,
and other risks and uncertainties set forth in Item 3.D. "Risk
Factors" section of our Annual Report on Form 20-F for the year
ended December 31, 2017 and subsequent reports that we file with
the U.S. Securities and Exchange Commission. We may not actually
achieve the plans, intentions, estimates or expectations disclosed
in our forward-looking statements, and you should not place undue
reliance on our forward-looking statements. Actual results or
events could differ materially from the plans, intentions,
estimates and expectations disclosed in the forward-looking
statements we make. We anticipate that subsequent events and
developments will cause our views to change. We are under no duty
to update any of these forward-looking statements after the date of
this press release to conform these statements to actual results or
revised expectations, except as required by law. You should,
therefore, not rely on these forward-looking statements as
representing our views as of any date subsequent to the date of
this press release. Any reference to our website address in this
press release is intended to be an inactive textual reference only
and not an active hyperlink.
Contact:
Senthil Sundaram, Chief Financial OfficerBrian Luque, Sr.
Manager, Investor Relationsinvestors@nightstartx.com
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Jul 2023 to Jul 2024